Optimizing the Care of Patients With Locally Advanced NSCLC With Multimodality Therapy

Area of Science:

• Oncology
• Pulmonology
• Radiotherapy

Background:

• Unresectable, locally advanced nonsmall cell lung cancer (LA-NSCLC) has poor long-term outcomes.
• Concurrent chemoradiotherapy (cCRT) is the standard, with durvalumab improving survival.
• Early progression and toxicity necessitate exploring new treatment strategies.

Purpose of the Study:

• To review evolving systemic and radiation-based treatments for LA-NSCLC.
• To highlight current limitations in LA-NSCLC management.
• To discuss future directions for improving patient outcomes.

Main Methods:

• Review of current literature on systemic therapies for LA-NSCLC.
• Analysis of advances in radiation delivery techniques.
• Evaluation of precision medicine approaches in NSCLC.

Main Results:

• Consolidative durvalumab significantly improves progression-free and overall survival in LA-NSCLC.
• Concurrent immune checkpoint blockade or intensified consolidation have not shown additional survival benefits.
• Precision medicine, including targeted therapy for oncogene-driven tumors, shows promise.

Conclusions:

• While durvalumab has advanced LA-NSCLC treatment, limitations persist.
• Individualized radiation strategies are crucial for optimizing local control and minimizing toxicity.
• Future research should focus on novel immunotherapy sequencing and precision medicine to improve outcomes.